Jon Zelner1,2, Joshua G Petrie1, Rob Trangucci3, Emily T Martin1, Arnold S Monto1. 1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor. 2. Department of Center for Social Epidemiology and Population Health, University of Michigan School of Public Health, Ann Arbor. 3. Department of Statistics, University of Michigan, Ann Arbor.
Abstract
BACKGROUND: Antibody waning following influenza vaccination has been repeatedly evaluated, but waning has rarely been studied in the context of longitudinal vaccination history. METHODS: We developed a Bayesian hierarchical model to assess the effects of sequential influenza A(H1N1)pdm09 vaccination on hemagglutination inhibition antibody boosting and waning in a longitudinal cohort of older children and adults from 2011 to 2016, a period during which the A(H1N1)pdm09 vaccine strain did not change. RESULTS: Antibody measurements from 2057 serum specimens longitudinally collected from 388 individuals were included. Average postvaccination antibody titers were similar across successive vaccinations, but the rate of antibody waning increased with each vaccination. The antibody half-life was estimated to decrease from 32 months (95% credible interval [CrI], 22-61 months) following first vaccination to 9 months (95% CrI, 7-15 months) following a seventh vaccination. CONCLUSIONS: Although the rate of antibody waning increased with successive vaccination, the estimated antibody half-life was longer than a typical influenza season even among the most highly vaccinated. This supports current recommendations for vaccination at the earliest opportunity. Patterns of boosting and waning might be different with the influenza A(H3N2) subtype, which evolves more rapidly and has been most associated with reduced effectiveness following repeat vaccination.
BACKGROUND: Antibody waning following influenza vaccination has been repeatedly evaluated, but waning has rarely been studied in the context of longitudinal vaccination history. METHODS: We developed a Bayesian hierarchical model to assess the effects of sequential influenza A(H1N1)pdm09 vaccination on hemagglutination inhibition antibody boosting and waning in a longitudinal cohort of older children and adults from 2011 to 2016, a period during which the A(H1N1)pdm09 vaccine strain did not change. RESULTS: Antibody measurements from 2057 serum specimens longitudinally collected from 388 individuals were included. Average postvaccination antibody titers were similar across successive vaccinations, but the rate of antibody waning increased with each vaccination. The antibody half-life was estimated to decrease from 32 months (95% credible interval [CrI], 22-61 months) following first vaccination to 9 months (95% CrI, 7-15 months) following a seventh vaccination. CONCLUSIONS: Although the rate of antibody waning increased with successive vaccination, the estimated antibody half-life was longer than a typical influenza season even among the most highly vaccinated. This supports current recommendations for vaccination at the earliest opportunity. Patterns of boosting and waning might be different with the influenza A(H3N2) subtype, which evolves more rapidly and has been most associated with reduced effectiveness following repeat vaccination.
Authors: Jill M Ferdinands; Alicia M Fry; Sue Reynolds; Joshua Petrie; Brendan Flannery; Michael L Jackson; Edward A Belongia Journal: Clin Infect Dis Date: 2016-12-29 Impact factor: 9.079
Authors: Edward A Belongia; Melissa D Simpson; Jennifer P King; Maria E Sundaram; Nicholas S Kelley; Michael T Osterholm; Huong Q McLean Journal: Lancet Infect Dis Date: 2016-04-06 Impact factor: 25.071
Authors: Elisabeth Huijskens; John Rossen; Paul Mulder; Ruud van Beek; Hennie van Vugt; Johannes Verbakel; Guus Rimmelzwaan; Marion Koopmans; Marcel Peeters Journal: Clin Vaccine Immunol Date: 2011-07-27
Authors: S Rastogi; P A Gross; J Bonelli; S Dran; R A Levandowski; C Russo; M E Weksler; D Kaye; M Levison; E Abrutyn Journal: Clin Diagn Lab Immunol Date: 1995-01
Authors: Emily T Martin; Caroline Cheng; Joshua G Petrie; Elif Alyanak; Manjusha Gaglani; Donald B Middleton; Shekhar Ghamande; Fernanda P Silveira; Kempapura Murthy; Richard K Zimmerman; Arnold S Monto; Christopher Trabue; H Keipp Talbot; Jill M Ferdinands Journal: J Infect Dis Date: 2021-06-15 Impact factor: 5.226
Authors: Wen-Chun Liu; Raffael Nachbagauer; Daniel Stadlbauer; Shirin Strohmeier; Alicia Solórzano; Francesco Berlanda-Scorza; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer; Randy A Albrecht Journal: Vaccines (Basel) Date: 2021-01-11
Authors: Annette K Regan; Meredith G Wesley; Manjusha Gaglani; Sara S Kim; Laura J Edwards; Kempapura Murthy; Zuha Jeddy; Allison L Naleway; Brendan Flannery; Fatimah S Dawood; Holly Groom Journal: Influenza Other Respir Viruses Date: 2022-04-12 Impact factor: 5.606
Authors: Amy C Sherman; Lilin Lai; Mary Bower; Muktha S Natrajan; Christopher Huerta; Vinit Karmali; Jennifer Kleinhenz; Yongxian Xu; Nadine Rouphael; Mark J Mulligan Journal: Vaccines (Basel) Date: 2020-11-07